Free Trial
LON:APTA

Aptamer Group Final Earnings Report

Aptamer Group logo
GBX 0.50 -0.03 (-4.76%)
As of 08:13 AM Eastern

Aptamer Group EPS Results

Actual EPS
GBX 0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aptamer Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aptamer Group Announcement Details

Quarter
Final
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Aptamer Group Earnings Headlines

Aptamer Group Regulatory News
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Aptamer Group PLC
See More Aptamer Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aptamer Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptamer Group and other key companies, straight to your email.

About Aptamer Group

Aptamer Group (LON:APTA) is a leading provider of aptamer selection services and developer of aptamer-based reagents for use in research, bioprocessing, diagnostic, and therapeutic applications. Headquartered in York, UK, the Company partners globally to deliver aptamer-based solutions that drive discovery and development across the life sciences. Aptamer Group has developed the proprietary Optimer® platform technology that drives three distinct businesses: Aptamer Solutions, Aptamer Diagnostics and Aptamer Therapeutics. Through the use of its Optimer platform the Company aims to enable new opportunities, including discovery and development partnerships for improved biologic drugs, and new applications, such as novel assays and targets, to accelerate discovery and improve current standard processes. For more information, visit: https://aptamergroup.com/

View Aptamer Group Profile